Solventum Guides FY Adjusted EPS to $7.20-$7.30
SOLV sits 40% above its 52-week low of $62.38 on elevated volume (1.8× avg).
Summary
Solventum put a fiscal-year adjusted EPS range of $7.20 to $7.30 on the tape. The company had already raised its 2026 adjusted EPS guidance in the Q2 report filed August 5, so this is the latest marker on that trajectory rather than a fresh surprise. The range is the key number for valuation here: at $87.18 a share, the midpoint implies a mid-teens earnings multiple, and any move toward the low end would compress that further. The prior quarter's print was clouded by a $204 million legal charge and the planned spin-off of the Health Information Systems business, both of which still hang over the story. In the third quarter the company posted adjusted EPS of $1.45, sales of $1.9B that fell slightly less than expected, and a loss per share of 7c, and it raised its full-year adjusted EPS outlook.
At the time of this announcement, SOLV was trading at $87.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $62.38 to $94.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.